InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder
InflaRx重啓了針對罕見皮膚病的第三階段藥物案例，該藥物此前曾被叫停。
InflaRx N.V. (NASDAQ:IFRX) is reviving hopes for vilobelimab after new analyses showed signs of efficacy in a Phase 3 trial it had previously halted, setting up FDA talks and a potential partner-led path forward.
InflaRx N.V.（納斯達克：IFRX）在新的分析顯示其此前暫停的第三階段試驗中vilobelimab有療效跡象後，重新燃起了希望，正準備與FDA進行會談，並可能通過合作伙伴推動未來發展。
Last Tuesday, the company outlined multiple data analyses of the Phase 3 study for vilobelimab in pyoderma gangrenosum (PG), which was terminated earlier in 2025 after an Independent Data Monitoring Committee (IDMC) recommended the trial be stopped early due to futility.
上週二，公司概述了針對壞疽性膿皮病（PG）中vilobelimab的第三階段研究的多項數據分析。該試驗於2025年初被終止，原因是獨立數據監查委員會（IDMC）因無效性建議提前停止試驗。
Subsequent post-hoc analyses suggest a positive trend in favor of vilobelimab, with signals indicating a potentially consistent treatment effect, the company said.
公司表示，隨後的事後分析顯示出對vilobelimab有利的積極趨勢，信號表明可能存在一致的治療效果。
Also Read...
另請...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
